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Abstract. 
The discovery and examination of the post-transcriptional gene regulatory mechanism known as 
RNA interference (RNAi), contributed to the   identification of small interfering RNA (siRNA) and 
the comprehension of its enormous potential for clinical purposes. Theoretically, the ability of 
specific target gene downregulation makes the RNAi pathway an appealing solution for several 
diseases. Despite numerous hurdles resulting from the inherent properties of siRNA molecule 
and proper delivery to the target tissue, more than 50 RNA-based drugs are currently under 
clinical testing. In this work we analyze the recent literature in the optimization of siRNA 
molecules. In detail, we focused on describing the most recent advances of siRNA field aimed 
at optimize siRNA pharmacokinetic properties. Special attention has been given in describing 
the impact of RNA modifications in the potential off-target effects such as saturation of the RNAi 
machinery, passenger strand-mediated silencing, immunostimulation and miRNA-like off-target 
effects as well as to recent developments on the delivery issue. The novel delivery systems and 
modified siRNA provide significant steps towards the development of reliable siRNA molecules 
for therapeutic use. 
 
Introduction 
 
The breakthrough of RNAi phenomenon1, 2 has incited the discovery of the core proteins of 
RNA-induced silencing complex (RISC)3, 4, the identification of the silencing trigger molecule5 
and the design of synthetic siRNA duplex6. Later on, the thrilling idea of siRNA target-specific 
signature, due to the necessity of perfect identity with its cognate messenger RNA (mRNA), had 
to deal with the silencing of unintended targets7. Furthermore, because of the inherent siRNA 
limitations (poor bioavailability, instability against nucleases, hydrophilicity and polyanionic 
nature), the development of RNAi-based therapeutics had suffered a serious slowdown. 
However, the ease of customization, the possibility of treating “undruggable” diseases and 
shortening the drug discovery process, have made siRNA-based therapeutics appealing agents 
for future tailored medicine (Figure 1). 
 
 
 
  
Figure 1. Benefits and drawbacks of siRNA-based therapeutics. In addition to important 
unwanted off-target effects such as the up- and down-regulation of thousands of unrelated genes, during 
the attempt of develop RNAi-based therapeutics some intrinsic siRNA limitations have been identified. 
Upon entering the bloodstream the siRNA molecules are promptly degraded and eliminated, the action of 
ribonucleases and reticuloendothelial system (RES) compromises its bioavailability under physiological 
conditions. Furthermore, the siRNA hydrophilicity, high molecular weight and polyanionic nature restricts 
its passive diffusion across cellular membranes. Even though all these serious issues, the siRNA 
properties can be adjusted in terms of gene silencing abilities (potency, specificity and efficacy). The ability 
of siRNA molecule to target any disease-related gene offers a valuable option to block the production of all 
those undruggable proteins, not-responding to traditional therapy, at the messenger RNA level. 
 
Theoretically, the siRNA nucleotide sequence should determine the specificity, potency and 
efficacy of siRNA-mediated gene silencing, but many factors influence its reliability. For 
example, the specificity, the ability to knockdown the target gene without interfering with the 
expression of other genes, is basically compromised by partial complementarity between the 
siRNA sequence and unintended targets. To ensure exact recognition of the target mRNA, 
chemical/structural modifications supported by bioinformatics tools have been extensively 
employed8, 9. But despite the great deal of efforts, the specificity remains one of the most 
challenging tasks for siRNA optimization. In addition, the mRNA accessibility affects the siRNA 
efficacy. The presence of secondary/tertiary structures on mRNA transcripts hinders the 
hybridization between the siRNA-programmed RISC and the target site sequence10, 11. Since 
excess amounts of siRNA saturate the RNAi machinery, the design of powerful siRNA 
molecules is indispensable. More powerful siRNA duplexes have been successfully synthesized 
using several chemical modifications.12. Finally, the implementation of siRNA activity for clinical 
applications should be addressed by the design of carriers able to deliver the silencing cargo 
into specific tissue. To enhance the siRNA bioavailability, its stability into biological milieu and 
overcome the physiological barriers after systemic administration, many delivery strategies have 
been evaluated13. Hence, the achievement of an optimized siRNA design strategy is possible, 
only taking into account all these issues. Here, we presented an overview focusing on the 
recent progress in siRNA field aimed at optimize siRNA pharmacokinetic properties. 
Furthermore, we outlined the recent advancements in delivery strategies. 
 
1. Dissecting the siRNA: chemical modifications and 
siRNA structure. 
 
1.1 How Argonaute splits the siRNA molecule 
Argonaute proteins are the fundamental components of the small-RNA-driven gene silencing 
mechanism. In human, eight Argonaute proteins have been identified; four of them belonging to 
Argonaute subcategory (hAgo 1-4) and the other four to the PIWI subcategory (hPIWI 1-4). 
Among them, only Ago2 possesses the ability to cleave the target mRNA14. Following the 
discovery of the core protein of RNAi pathway, intensive studies have defined its domain 
composition. The hAgo2 has revealed cradle shaped architecture and highly conserved 
domains: MID, PIWI, PAZ and N-lobe4 (Figure 2). The MID interacts with the first nucleotide (5’-
phosphorylated) at the 5’-end of the siRNA guide strand15. The PIWI motif, harboring the 
RNase-H like catalytic core of Ago2, is responsible for the endonucleolytic cleavage of the 
target mRNA16. The PAZ domain is a hydrophobic cavity able to recognize the 3’ terminal 
dinucleotide overhang of the siRNA strand17. Finally, the N-lobe acting as a molecular wedge, is 
strictly required for duplex unwinding and maturation of RISC18. Thanks to the 3’ terminal 
unpaired dinucleotide structures and 5’ phosphate group, the Argonautes can efficiently identify 
the siRNA/miRNA (microRNA) molecules among other small RNAs19. Moreover, the RISC is 
able to discriminate between double stranded (ds) RNA and dsDNA molecules, only the formers 
are powerful triggers of gene silencing. Unlike dsDNA, that adopts a B-form conformation (right-
handed helix, 10bp per helical turn and 20 Å in diameter), dsRNA displays an A-helix motif and 
one helical turn containing 11 bp with a diameter of 23 Å. The wider major groove of the A-form 
helix is needed for stable interactions with RISC and target mRNA20. 
Upon RISC assembly and the degradation of the passenger strand, Ago2 functionally classifies 
the guide strand into 5 discrete sections: (i) anchor; (ii) seed; (iii) central; (iv) 3’ supplementary 
and (v) tail21 (Figure 2). 
 
 
 
 
 
 
 
 Figure 2. Ago2 diagram and siRNA molecule. Top strand is the passenger or sense, 
bottom strand is the guide or antisense. The passenger strand during RISC maturation is nicked 
and degraded, whereas the guide strand is retained and serves as complementary sequence for 
the identification of the target mRNA. 
 
1.1.1 The anchor site (1) 
The first nucleotide of the guide strand (Figure 2 in red) is stably buried into the MID domain of 
Ago2 protein and is not actively engaged in target recognition22. Moreover, the presence of 
phosphate group at 5’ terminus is essential for siRNA efficacy23, 24, the phosphorylation of the 5’-
end is also required for strand loading and proper Ago2-mediated cleavage. 
Even though the MID pocket provides adequate space to the accommodation of the natural 
bases, the presence of uridine or adenine is preferred over guanine and cytosine15, 25. The 
interactions between the MID cleft and the different natural bases are essentially not-specific 
and the identity of the interacting MID-nucleotide does not disturb the overall protein structure. 
Detailed studies on nucleobase recognition by the MID domain have revealed the presence of a 
well-arranged water network able to mediate contacts between several residues (Met 437, Lys 
440, Ile 477 and Asp 480) and the N6 of the adenine26. Furthermore, Schirle and co-workers 
have suggested that the identity of the first nucleotide of the guide strand is not decisive for the 
initial recognition of the target mRNA but is crucial for increasing the stability between the Ago2 
and the mRNA after seed-pairing nucleation. 
Computational screenings of MID pocket and in vitro tests have also identified new 5’ end 
modifiers able to enhance siRNA potency27. For example, bulky adenosines analogues have 
demonstrated to accommodate poorly into the MID pocket, their introduction at the 5’end of 
siRNA molecules were detrimental for RNAi activity in comparison with the natural adenosine. 
On the other hand, siRNAs modified with triazole derivatives, fitting better into the 5’-nucleotide 
binding pocket, have revealed stronger silencing activity with respect to unmodified siRNA 
molecules. 
1.1.2 The seed region (2-8) 
The stretch from position 2 to 8 (Figure 2 in green), well known as the seed, is responsible for 
the initial base-pair formation during the nucleation step of target recognition28. Proper seed 
pairing is important for both miRNA and siRNA target recognition29, but is also critical for serious 
unintended miRNA-like OFF-target effects30. SiRNA molecules with different AU or GC content 
in the seed region have revealed opposite performance in terms of seed-matched target(s) 
silencing. The presence of four to seven A/Us in the seed stretch has proved to effectively 
reduce the seed-off target silencing while sustaining high activity for target gene31. Thus, the 
reduction of seed thermodynamic stability can diminish the siRNA seed-dependent off-target 
effects32. Moreover, the modification of the seed sequence with UNA (Unlocked Nucleic Acid) 
moieties has demonstrated to reduce the siRNA off-target potential. The presence of UNA 
modification locally destabilizing the RNA-RNA hybridization impacts more heavily on partial 
target recognition, responsible for the miRNA-off target effect, rather than on fully 
complementary target binding. For instance, the introduction of one UNA unit at 3’-end of the 
seed stretch has dramatically reduced the silencing mediated by partial complementarity without 
affecting the siRNA potency33.  
Even though strong interactions can be prevented using AU-rich seed siRNAs or UNA seed 
modified siRNA, it was demonstrated that 3’ supplementary region actively contributes to OFF-
target effects, neutralizing the influence of 5’ base pairing34, 35.  
The modification of guide seed with 2’-O-methyl-RNA moieties (Figure 3), especially at position 
2 of the guide strand, has also resulted in reduced silencing of off-target transcripts36. Of note, 
position 2 of the guide strand also plays an important role in ON-target recognition, 2’-O-
methoxyethyl-RNA modification (Figure 3) has demonstrated to be detrimental for adequate 
target binding and Ago-mediated cleavage23. To diminish the stability between guide seed and 
mRNA, the seed region was also replaced with DNA units37. Since the DNA/RNA hybrid is less 
stable than RNA homoduplex, weaker interactions help to hinder the target duplex nucleation in 
absence of supplementary interactions beyond the seed sequence. Because the seed portion 
needs to be arranged within the Ago into a perfectly ordered A-form helix38, the DNA/RNA 
helical deviation from A-form geometry is most likely detrimental for target recognition and seed-
mediated activity. Further studies, on correlation between helical distortion and proper target 
binding, remarked upon the importance of A-form duplex geometry for the Ago-mediated mRNA 
initial recognition. Increasing numbers of mismatches along the seed stretch, entailing local 
distortion of the duplex structure, lead to a general “decoupling” between the guide and the 
mRNA. Central seed mismatches (4 – 5 positions) heavily weigh on Ago processivity more than 
those closer to the seed ends21. Furthermore, single wobble base pair (G:U) within the seed 
sequence has demonstrated to be a good strategy able to efficiently abrogate the off-target 
silencing39, 40. Thus, both duplex stability and structural parameters contribute to the 
effectiveness of guide-mediated off-target silencing. 
 
 Figure 3. Chemical structures of modified backbones used in siRNA. 
 
1.1.3 The central region (9-12) 
Central base pairs (nucleotides 9 – 11) (Figure 2 in yellow) lying within the catalytic part of the 
Ago2 protein support the cleavage of the target mRNA. Central base pair matches are required 
for RISC maturation and for the correct conformation of the Ago’s active site. Passenger strand 
is the first RISC target, its cleavage helps the dissociation from the guide strand and the 
production of the active RISC41. Slicer-dependent maturation of the RISC is the main 
mechanism for the elimination of the passenger strand. Phosphorothioate substitution of the 
scissile phosphodiester group makes the passenger strand non-cleavable and promotes a 
slower bypass mechanism in which the duplex unwinding is cleavage-independent42, 43. The 
substitution of central nucleotide pairs with DNA units has demonstrated to lower the silence 
activity, the deviation from canonical A-form structure of the guide:mRNA duplex likely leads to 
poor cleavage capability. On the other hand, replacement of central nucleotides either on guide 
or passenger strand marginally affects the inhibition, probably because hybrid DNA/RNA 
molecules, assuming a helical conformation between the A- and B-form, are less detrimental for 
the slicing44. Modifications, which prefer C3’-endo conformation, and stabilize the local RNA 
structure in A-form geometry (i.e. 2’-O-methyl, 2’-Fluoro, 2’-O-methoxyethyl, Pseudouridine, 2’-
Thiouridine), have proved to be tolerated at central positions of guide strand40, 23, 45, 46. 
Conversely, more flexible units such as Dihydrouridine and L-threoninol-thymine (Figure 3), 
increasing the flexibility of duplex geometry inhibit the silence activity40, 47. Thus, proper RNA A-
form geometry, around the cleavage site, is essential for adequate Ago2-mediated catalysis. 
The perturbation of Ago2 catalytic efficiency in presence of central mismatches has once more 
confirmed the importance of proper duplex arrangement within the cleavage site21. 
1.1.4 The 3’-supplementary region (13-18) 
The 3’ supplementary region (Figure 2 in pink) is responsible for the propagation of duplex 
formation over the central cleavage region. In binary complex, the nucleotides 14-18 are 
surrounded by a narrow channel formed between the PAZ and N domains, their base stacking 
interactions are broken and nearly all Watson-Crick edges point inward. The extensive contacts 
with the Ago2 protein prevent the hybridization between the guide 3’-half and the 
complementary target. Conversely, the arrangement of guide-target pairing beyond the 5’-half 
portion leads to significant conformational changes, the PAZ-N channel gets wider and the 
guide 3’-half is repositioned forming A-form helix22. Stable hybridization between the stretch 14-
18 and the target also facilitates the correct positioning of central nucleotides and the cleavage 
activity28. 
1.1.5 The tail region (19-21) 
The terminal part of the guide strand spans nucleotides 19 – 21 (Figure 2 in blue) and 
comprises a dinucleotide-unpaired structure, named overhang, which protrudes from the siRNA 
duplex and specifically interacts with PAZ pocket19. Even though the 3’-overhang does not 
actively participate to target recognition, its presence is critical for siRNA activity48. Along with 
the interaction between the 5’end and the MID pocket, stable anchoring of 3’-end within the PAZ 
domain is essential for the proper unwinding and passenger release28, 49. During the formation 
of catalytically competent RISC the passenger strand is nicked and discarded, its elimination 
permits the propagation of base pairing towards the guide 3’-end and facilitates the 
displacement of the overhang from the PAZ cleft. Once the cleaved products are released, the 
PAZ domain again fastens the guide 3’-end. The PAZ motion, according to the “two state” 
model, has permitted the elucidation of the siRNA-programmed RISC catalysis as a multiple 
turnover process50. The lodging/dislodging motion is regarded to be a decisive factor in boosting 
siRNA potency. Likely, more affinity for the PAZ cleft, favoring a rapid increase of the 
fasten/unfasten rate, accelerates the RISC cleavage turnover. So, in view to improve siRNA 
potency, through the strengthening of the interactions between the 3’ guide overhang and the 
PAZ pocket, numerous overhang modifications (Figure 3) have been tested51-55. Of note, the 
size of overhang modification, affecting the proper accommodation into the PAZ hydrophobic 
cavity, influences the siRNA activity56-58. Because of the extreme RNA instability in biological 
milieu, overhang modifications have been primarily developed to protect the siRNA integrity 
from the action of nucleases6. Thereafter, the detection of siRNA-associated side effects has led 
to evaluate the ability of overhang-modified siRNAs in promoting the correct strand selection59. 
For example, thanks to different binding affinity of modified overhang, chemically asymmetric 
siRNAs have demonstrated to improve the loading of the intended strand60. Indeed, the 
enhanced siRNA potency is likely the result of preferential loading of the strand bearing the 
overhang with better PAZ binding affinity. The favored guide strand incorporation impedes the 
passenger strand misloading, preventing the passenger-mediated OFF-target effects. 
Remarkably, the absence of passenger strand overhang, eliminating the structure recognized 
by the PAZ domain, promotes the loading of the strand bearing the overhang61. Furthermore, 
overhang-modified siRNAs have extensively employed to induce long-term gene silencing. 
Enhanced stability towards nucleases has been assumed to endure the silencing effects, even if 
later studies have clarified that the silencing duration in vitro depends mostly on the cellular 
doubling-time rather than improved stability62, 63. Thus, nuclease-stabilized siRNA has more 
influential impact during in vivo delivery of naked molecules64. 
2. Handling the OFF-target effects (OTEs) 
The development of siRNA-based therapeutics, straight after an initial burst, has suffered a 
setback caused by ever-growing issues questioning on their biological safety. Unintended side-
effects of siRNA-mediated gene silencing essentially hinge upon: (i) suppression of non-target 
genes; (ii) saturation of RNAi machinery; (iii) passenger strand mediated silencing; (iv) immune 
response activation (Table 1).  
 
Table 1. Schematic summary of siRNA-mediated OTEs 
 
2.1 Saturation 
The estimated RISC concentration inside the cells ranges between 3 – 5 nM. RISC amount, 
considering the average volume of a mammalian cell (10-13 L – 10-12 L), is in the order of about 
103 – 104 molecules65. Thus, saturation of the RNAi machinery is theoretically reached with 10 -
100 pM siRNA, which corresponds to 103 – 104 dsRNA molecules. The transfection of 
exogenous siRNAs principally leads to competition for RISC binding between the endogenous 
miRNA pool and the exo-siRNAs. MiRNA displacement influences the miRNA-mediated 
OFF-target type Effects Solutions 
Saturation of RNAi 
machinery 
Up-regulation of miRNA-
controlled genes 
Improve siRNA potency by chemical 
modifications12, 58, use highly potent siRNA 
molecules59, 60 
Passenger strand-
mediated silencing 
Down-regulation of mRNA 
target(s) partially and/or 
fully complementary to 
passenger strand 
Enhance thermodynamic asymmetry, 
blunt end siRNA53, si-siRNA67, asiRNA53, 
68, 69
, aiRNA70, ss-siRNA71, block 
passenger 5’-end phosphorylation63-65, 
dual targeting siRNA73, 74, 75 
Seed-mediated 
silencing 
Down-regulation of 
partially complementary 
genes 
Avoid common seed complementary 
sequences98, AU-enriched seed99 
Immunostimulation 
Induction of inflammatory 
cytokines and type-I 
Interferons 
Avoid immunostimulatory motifs78, 79, 
escape the immune system recognition by 
chemically modified siRNAs83 
silencing and leads to an overall upregulation of miRNA-controlled genes. The preservation of 
robust silencing effects with lower dose is advantageous in terms of RISC competition. For this 
reason, the design of potent siRNA molecules fundamentally aims at the prevention of RISC 
clogging. If only a fraction of cellular RISC pool is actively occupied by the exo-siRNAs, more 
RISC molecules are available for endogenous pathways.  
Besides canonical modified siRNAs (extensively reviewed elsewhere12, 66), which demonstrated 
to be more potent with respect to the unmodified ones, innovative approaches based on new 
siRNA structural variants have been applied. For instance, Dicer substrate interfering RNAs 
(DsiRNAs) have demonstrated stronger activity with respect to canonical 21-nt siRNAs. Dicer 
executing the conversion of DsiRNA precursor into active siRNA, assists the Ago loading and 
raises the RISC incorporation rate. In addition, adequate strand polarity conferred by DsiRNAs 
minimizes the incorporation of the passenger strand into the RISC67. Another successful 
example of potent siRNA precursors emerges from the synthesis of dumbbell-shaped circular 
siRNA: a circular RNA molecule that folds into a central stem region and 2 terminal loop 
structures. Interestingly, dumbbell-shaped siRNA, with 23-bp stem region and 9-nt long loops, 
has disclosed powerful improvement on silencing activity with respect to canonical 21-bp 
siRNA. The lack of loose ends, distinctive of siRNA structure, entails better resistance towards 
nucleases and reduced activation of innate immune response. Furthermore, the slow Dicer 
processing of dumbbell siRNA, likely allowing a gradual but constant production of active siRNA 
molecules, drives long-lasting silencing68.  
 
2.2 Passenger strand mediated silencing 
The claim assuring:” the strand with less stable 5’-end is preferentially incorporated into RISC 
and serves as the guide”, holds back the possibility of improper strand incorporation. It has 
been established that passenger strand could be efficiently loaded as the guide strand, 
provoking the downregulation of complementary target(s)69. Passenger strand-driven silencing 
compromises siRNA specificity and engulfs the RNAi machinery with the wrong strand. To 
promote the correct strand election, chemical and structural approaches have been 
investigated. Since the presence of 5’ terminal phosphate is strictly required during RISC 
assembly and is essential for silencing activity70, chemical modifications able to block the Clp-1-
mediated 5’end phosphorylation, permit desirable strand incorporation or limit passenger strand 
activity71, 35, 72, 73. Moreover, passenger seed substitutions, altering the duplex stability between 
the modified strand and the target mRNA, prejudice its ability to participate in target cleavage33, 
35, 47, 54
. Hence, strand-blocking properties of chemical modifications are successfully exploited 
to weaken the passenger strand-mediated silencing. It was also noted, that in the absence of 
passenger overhang, the activity and the strand selection of blunt siRNAs incline towards the 
guide strand61. Given that the presence of overhang is decisive for PAZ-mediated RISC 
recruitment, the asymmetrical structure of blunt siRNA promotes the loading of the strand 
carrying the overhang.  
In order to improve the poor inherent siRNA properties (especially the specificity), novel siRNA 
architectures have been analyzed. For example, new siRNA construct has originated as a result 
of the development of LNA (Locked Nucleic Acid, Figure 3) modification. Internal segmented 
siRNA (si-siRNA) consisting of a 22-nt guide strand and 2 segmented (10 + 12 nt) passenger 
strands has demonstrated to be as effective as canonical siRNA. Furthermore, the three-
stranded siRNA composition, combining the LNA stabilization effect on passenger strands and 
the silencing inability of shorter passenger strand portions, has proven to be an highly specific 
siRNA architecture74. Therefore, passenger shortening can be an intriguing approach to the 
elimination of passenger strand-mediated silencing. Asymmetric shorter duplex siRNA 
(asiRNA), asymmetric siRNA (aiRNA) and blunt end siRNA61, 75-77 have exhibited silencing 
ability comparable to canonical siRNA structure and less siRNA-mediated off-target effects. 
Interestingly, the progressive passenger strand trimming from its 5’-end does not compromise 
RISC assembly and its off-target effects. On the other hand, the shortening of the passenger 3’-
end promotes the preferential loading of the opposite strand. Even though the thermodynamic 
asymmetry of siRNA duplex contributes to guide strand selection, the presence of the 3’ 
overhang substantially weighs on strand preference. 
Since active RISC needs only one strand to execute the cleavage of the target mRNA, single-
stranded siRNA (ss-siRNA) was able to trigger gene silencing78. This strategy completely 
abolishes the passenger-mediated silencing but has disclosed decreased potency with respect 
of double stranded siRNAs. Furthermore, 5’ unphosphorylated ss-siRNA are not functional, only 
the chemical addition of a phosphate at 5’-end rescues the silencing activity79. In single-
stranded fashion, the endogenous phosphorylation is likely hindered, so only pre-
phosphorylated ss-siRNA can stably interact with the RISC. An appealing solution to passenger 
off-target effects came from dual targeting siRNAs, which harbor two functional strands. Since 
each strand individually recognizes distinct targets, the passenger-driven silencing is virtually 
eliminated80, 81. Fundamentally, the key steps for correct dual-targeting design are the choice of 
target genes and the calculation of termini stability. Bioinformatics analysis on gene candidates 
facilitates the selection of partial overlapped sequences able to form stable multi-bulged duplex 
siRNA. Moreover, computation of balanced ends permits unbiased strand incorporation and 
confers comparable effectiveness to both strands82. 
 
2.3 Immunostimulation 
The innate immune system has evolved to support rapid response by the recognition of 
pathogen hallmarks. Pattern recognition receptors (PRRs) identify pathogen-associated 
molecular patterns (PAMPs) exclusively present on microorganisms. The innate immune 
sensors perceive exogenous RNAs as a viral infection, the resulting activation of the defense 
mechanisms leads to the production of type I interferon and pro-inflammatory cytokines. 
Sensors designated to the recognition of non-self RNAs belong to TLR (Toll-Like Receptor) and 
non-TLR pathways83. TLRs receptors located at endosomal compartment are the first line of 
defense against viral RNA infections. Their almost exclusively compartmentation also dictates 
the discrimination between host and non-self nucleic acids. TLRs (TLR3, TLR7, TLR8 
andTLR9) specifically interact with stimulatory motifs present on double and single-stranded 
RNA84. Even though it was noted that some secondary structures stimulate the activation of 
TLRs, their activation is mostly sequence-dependent. Indeed, polyuridine tracts and GU-rich 
sequences, are strong RNA immunostimulatory motifs that should be avoided in tailored-
designed siRNA85, 86. Among the most important no-TLR receptors, PKR, RIG-I and OAS 
recognize dsRNA in a sequence-independent manner87. DsRNA-dependent protein kinase 
(PKR) and 2’-5’-oligoadenylate synthetase (OAS) activation restricts viral transcription and 
translation by blocking cellular protein synthesis and induction of apoptosis88. The 5’-
triphosphate presence on dsRNA structures triggers RIG-I-mediated antiviral signaling89. Many 
efforts have been made to develop siRNA molecules able to escape the innate immune 
recruitment. SiRNA chemical modifications, able to mitigate the activation of immune response, 
permit to identify the basic hallmarks recognized by the immune sensors. Ribose 2’-position 
modifications, such as 2’-OMe, 2’-F and 2’-H, have demonstrated to strongly reduce the levels 
of IFNs while retaining optimal siRNA-silencing90. New approaches based on minor-groove 
base modifications have aimed at protection of immunostimulatory hot spot present on miRNA–
mimic91. Furthermore, adenine substitution over the other nucleotides has beneficial effects on 
eluding the immune recognition92, 93. Although the necessity of neutralizing the 
immunostimulatory potential of siRNA molecules is fundamental goal to achieve for reliable 
therapeutic purposes, the siRNA adjuvant effect has been exploited to activate the cellular 
immunity. A promising approach for cancer and viral therapy came from the development of 
immunostimulatory siRNAs (is-siRNAs)86, 94. These bifunctional molecules, linking potent gene 
silencing properties to suitable production of IFNs, can effectively control chronic viral diseases 
such as HIV-AIDS, HBV and HCV infections95-97. Furthermore, the application of this new siRNA 
design can not only overcome the cancer drug resistance, but also strengthen the immune 
surveillance usually evaded by cancer cells98-102 
 
2.4 miRNA-like OTEs 
Analysis of multiple microarray datasets has revealed widespread siRNA-driven gene down-
regulation 30, 103. The mechanism underlying siRNA off-targeting resembles that miRNA-based: 
seed base-pairing interactions between the guide strand and the mRNA (especially in the 
3’UTRs), are sufficient to suppress the expression of unintended targets7. MiRNA-like silencing 
produces false-positive data and toxic phenotypes contributing to the problematic interpretation 
of silencing outcomes and weakening the potential therapeutic benefits of siRNA-based drugs. 
To mitigate the off-target effects, several modifications such as single nucleotide bulge, UNA 
and 2’-OMe moieties were introduced within seed sequence. The presence of these 
modifications has proven to ameliorate the siRNA specificity without reducing the siRNA 
efficiency30, 35, 104. To prevent the miRNA-like silencing, an alternative path comes from the study 
of seed complement frequencies (SCFs) in the 3’UTR transcriptome. It is well-described that 
each siRNA molecule presents specific off-target fingerprint. Fluctuations in off-target signature 
essentially rely on seed nucleotide sequence mirroring the complementary target abundance in 
the 3’UTR genome. Thus, fewer off-target silencing and lower false positive scores can be 
obtained avoiding the introduction within the seed portion of high-frequency seed 
complements105. Since seed-mediated recognition of complementary transcripts is sufficient to 
determine miRNA-like off-target silencing, the weakening of pairing stability between guide seed 
portion and target mRNAs optimizes the siRNA stringency31.  
3. Delivery 
The task of designing potent, highly specific and effective siRNA molecule is only the first 
checkpoint to cross for the development of siRNA-based therapeutics. Given that siRNA 
molecule has to reach the cytoplasm to fulfill its function, the tissue delivery becomes a 
fundamental priority to address106. After intravenous injection, siRNA starts to be systemically 
distributed and eliminated from the blood stream. To be recruited by the cytoplasmic RISC, the 
siRNA molecule has to overstep several barriers including interstitial/extravascular milieu and 
endolysosomal compartment107. Systemically delivered naked unmodified siRNAs, are 
subjected to the degradation by serum nucleases and elimination by the ReticuloEndotelial 
System (RES). Moreover, because of its high molecular weight and polyanionic/hydrophilic 
nature, siRNA molecules cannot easily diffuse across the cell membrane. Thus, the extremely 
short half-life and the negative physicochemical features of siRNAs have impeded the 
administration of non-protected siRNA-based drugs. Even though local administration has 
provided a valid alternative to avoid the systemic route and direct access to an interested 
region, is only suitable for easily accessible tissues (i.e. eye). Systemic administration remains 
essential for the treatment of solid tumors, but the poor pharmacokinetic profile of unformulated 
and unmodified siRNAs renders unfeasible their systemic delivery. In order to optimize the 
delivery process, carriers should comply with some rules. Prolonged blood circulation time, for 
example, is attained maintaining the vehicle particle size between 70-200 nm. The obtained 
stealth properties essentially depend by the escape from phagocytic clearance and rapid renal 
elimination. Moreover, broad interactions with serum components (i.e. lipoproteins, complement 
proteins, albumin), which interfere with bio-availability and promote unspecific uptake by liver, 
spleen and RES (ReticuloEndothelial System), prevent the reaching of the target. The shielding 
effect of hydrophilic molecules (i.e. PolyEthylene Glycol or PEG) covering the surface of delivery 
vehicles, is exploited not only for minimizing the interactions with serum proteins but also 
provide an adequate solution to avoid the activation of the innate immune system108. The 
modification of the internucleotide phosphate linkage, replacing one non-bridging oxygen with 
one sulfur atom, alleviates the immunostimulation and improves the nuclease stability. Targeted 
delivery aims to address the siRNA drug toward specific tissue or cell populations with 
negligible toxicity for other tissues. Passive targeting takes advantage of leakiness in tumor 
vessels permitting carrier extravasation, whereas active targeting has the intention of limiting 
the delivery toward a specific target109. With the exception of hepatic delivery, passive targeting 
is not a feasible approach due to heterogeneity on tumor vascularization and tumor vessel 
porosity. Diverse conjugation chemistries able to link specific target molecules (i.e. antibody, 
peptides, aptamers, small molecules) to siRNA cargo, employ the specific ligand-receptor 
recognition for the uptake of certain tissue or cells110. Upon receptor-mediated endocytosis the 
delivery cargo is incorporated into the endosomal trafficking, final fusion of endosomes with 
lysosomes acidifies the lumen and liberates the nucleases promoting the degradation of siRNA. 
The rapid escape from endolysosomal compartment releases the siRNA into the cytosol and 
permits the association with RNAi machinery. Fusogenic lipids and pH-sensitive carriers (i.e. 
proton escape) are some of successful strategies used for enhance the endosomal escape 
while protecting the siRNA from degradation111. 
Of note are also self-assembled RNA superstructures, which consist of hairpin RNA structures 
condensed in sponge-like spherical fashion (Table 2). Thanks to the use of RNA polymerase it 
is possible to generate RNAi-microsponges containing about 100000 siRNA copies. The Dicer 
processes the hairpin RNA precursor and directly liberates active siRNA molecules into the 
cytosol. Furthermore, the adsorption of polyethyleneimine (PEI) onto the negatively charged 
RNAi-microsponge, creating a net positively charged outer layer, facilitates the cellular uptake. 
This self-assembled carrier yielding great siRNA loading, customized siRNA composition, stable 
protection from degradation, low cytotoxicity and efficient gene silencing is a promising solution 
to delivery112. Additional relevant means for siRNA delivery have come from the discovery of 
exosomes and HDL particles able to shuttle RNAs between cells113, 114. Intriguing novel delivery 
approaches mimicking materials from endogenous sources has paved the way to the 
development of exosome-based vehicles (Table 2). Their endogenous derivation, impeding the 
recognition, the opsonization and clearance by immune system, gains crucial advantages over 
the other polymer-based and lipid-based carriers. Moreover, the release of the cargo directly 
into the cytosol, allows the bypass of the endosomal escape115, 116. Additionally, starting from 
the nature and the structure of native HDL, biomimetic lipoprotein carriers have been developed 
for efficient delivery in vivo. Reconstituted HDL-like particles (rHDL), HDL-mimicking 
nanoparticles are some examples of flexible, not immunological active vehicles able to transfer 
the siRNA cargo directly into the cytosol (Table 2)117, 118. 
 
 
 
 
 
 
 
 
Delivery vehicles Derivation Advantages 
Microsponges106 
Enzymatic 
polymerization 
Stealth effects, customization of siRNA 
composition, stability in biological environment, 
high-yield siRNA loading 
Exosomes109, 110 Endogenous 
Stealth effects, release of the cargo directly into 
the cytosol, not immunogenic 
HDL-like 
particles111, 112 
Endogenous/biomimetic 
Stealth effects, bypass the Endosomal 
compartment, immune-inert formulations 
 
TABLE 2. Most recent delivery strategies 
 
CONCLUSION 
 
Deep understanding of RNAi pathway and nucleic acid delivery has its ultimate goal in reducing 
the unintended effects without compromising the silencing properties. Each step of design, 
synthesis and delivery of siRNA-based drugs requires adequate optimization. Rational design of 
siRNA molecules and tailored engineering of delivery vehicles has promoted giant progress 
toward clinical application. Modified siRNA provided the design of potent, highly specific and 
effective molecules, whereas multifunctional carriers have permitted the improvement of siRNA 
stability during systemic delivery and cell-specific targeting. 
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